News

orange__line
Post ASGO GU 2018

MedSIR team attended ASCO GU 2018 in San Francisco, where experts discussed emerging targets, diagnostics, therapies in advanced prostate Cancer among other key relevant topics...
READ MORE...
MedSIR INSIDE OUT – Joan Cama

Today we are happy to spend a brief moment with Joan Cama, who joined MedSIR in May 2016 as our Financial and IT Department Manager. MedSIR Newsletter Team (MS): Thanks, Joan...
READ MORE...
1000 Patients!

Congratulations! All together we've made it to 1000! Perhaps this milestone was reached quicker than we thought when MedSIR first began about 6 years ago with the idea in mind of bringing people together to help as many...
READ MORE...
INTERVIEW: Oncologist of the Month – Dra. Begoña Bermejo

Today, we had the chance to sit down with Dra. Bermejo, Breast Cancer Specialist and our MedSIR Oncologist of the Month. Here’s an excerpt from our conversation: Thanks so much...
READ MORE...
WELCOME HOME LINGain study!

Dual HER2 blockade with trastuzumab and pertuzumab in the neoadjuvant setting is considered a more robust treatment approach with significant antitumor activity compared to...
READ MORE...
MedSIR will be there: ASCO GU

MedSIR will be making its second straight appearance at the annual ASCO GU Congress, this time held under the beautiful California sunshine in San Francisco. With MedSIR growing very steadily...
READ MORE...
Post SABCS 2017

When we got off the plane in San Antonio on the evening of December 4th, nobody could imagine what was going to transpire over the next 4 days! After over 30 meetings the MedSIR team is still...
READ MORE...
Immunotherapy Studies

A few years ago, MedSIR organized a successful Think Tank event in Barcelona, Spain that revolved around the exciting new field of Immunotherapy in Cancer. Many young and established...
READ MORE...
MedSIR INSIDE OUT – Maria Sió

Today we are happy to spend a brief moment with Maria Sió, International Trial Lead at MedSIR. MedSIR Newsletter Team (MS): Thanks, Maria, for spending some time with us...
READ MORE...